Pegylated Human granulocyte colony-stimulating factor (PEG-G-CSF) is a covalent conjugate of recombinant human G-CSF (Filgrastim) and a 20 kDa monomethoxy polyethylene glycol (mPEG).

Pegfilgrastim was developed and marketed by Gennova in India under the brand name PEGEX^®. PEGEX^® was launched in March 2010 and is indicated as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

Both Pegfilgrastim and filgrastim have the same mechanism of action except that the Pegfilgrastim has reduced renal clearance and prolonged persistence in vivo as compared to Filgrastim. Pegfilgrastim (PEGEX^®) is supplied as a pre-filled syringe containing 6 mg / 0.6 ml of Pegfilgrastim with automatic needle shielding system from BD Preventis^TM .